Healthcare / BiotechnologyOslo
$3.50
+0.37 (+11.64%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-51.3M · quality 79.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-13.4%
↓Gross Margin
N/A
•Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
2.41x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-12.2M · FCF $-29.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $8.7M | $12.9M | $7.2M |
| Net Income | $-12.2M | $-12.2M | $-38.8M | $-35.2M | $-42.7M |
| EBITDA | $-15.5M | $-15.5M | $-43.1M | $-41.7M | $-48.9M |
| EPS | -0.04 | -0.04 | -0.12 | -0.12 | -0.15 |
| Operating Margin | — | — | -556.9% | -450.2% | -741.6% |
| Net Margin | — | — | -447.3% | -272.5% | -596.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 |
| Current Ratio | 12.66 | 12.66 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-29.5M | $-29.5M | $-51.3M | $-98.5M | $-23.4M |
| Returns | |||||
| ROE | -13.4% | -13.4% | -28.5% | -20.5% | -27.2% |
| Valuation | |||||
| P/B | 12.49 | 12.49 | 7.25 | 33.52 | 53.77 |
| Growth & Yield | |||||
| Revenue Growth | — | — | -32.7% | 80.0% | — |
| EPS Growth | 66.7% | 66.7% | 0.0% | 20.0% | — |
| Dividend Yield | 29.8% | 29.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+112.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.12 → -0.04
Residual
+82.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.